Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital in connection with its acquisition of Blika Solutions AB
Mandate

Vinge has advised Main Capital in connection with its acquisition of Blika Solutions AB

April 06, 2022 Employment and Benefits M&A Intellectual Property IT, Telecommunications and Outsourcing Commercial Agreements

Blika provides a modular, best-of-breed SaaS system which allows companies to monitor legal structures ensuring proper governance and compliance. The platform helps enterprises to comply with tax, legal and transfer pricing regulations such as DAC6 and IFRIC 23.

Blika is headquartered in Stockholm with additional offices in Kalmar and Oskarshamn and has a large client base comprising European and global multinational businesses including Fortune 500 companies.

Vinge’s team consisted of Filip Öhrner, Manne Bergström, Egil Svensson (M&A), Veronika Garemark, Elin Broman (Employment), Rebecka Målquist (IP), Lisa Hörnqvst, Karolina Fuhrman (Commercial Agreements, IT & GDPR) and Jessica Henning (VDR Assistant).

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026